skip to content


Abzena signs new ThioBridge licence agreement

20 January 2017 07:53

Abzena has signed a licensing agreement for its novel site-specific ThioBridge antibody drug conjugate (ADC) linker technology with a San Diego-based biopharmaceutical company.

ThioBridge links antibodies and other proteins to drugs.

Abzena saiid: "The technology platform is unique in its ability to maintain the stability of the antibody and a consistent drug-to-antibody ratio (DAR), which provides a more homogeneous product."

The agreement covers the use of ThioBridge in up to 10 ADCs across a wide range of indications.

Abzena has also entered a master services agreement, which enables multiple programmes of work to be undertaken over an extended period, relating to the group's chemistry services.

The value of the agreement to Abzena has the potential to reach over $300m, comprising licence fees and milestone payments.

In addition, Abzena would also receive royalties on sales of approved products that incorporate the ThioBridge technology developed by its partner.

Story provided by

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.